Amgen cutting 300 Onyx jobs 19 months after merger
This article was originally published in Scrip
Executive Summary
Well over a year after the $10.4bn acquisition of Onyx Pharmaceuticals, Amgen still is consolidating operations and cutting Onyx jobs, according to a recent memo from chairman and CEO Robert Bradway to Amgen and Onyx employees, which warned of 300 upcoming job cuts.